Skip to main content
Clinical Trials/JPRN-UMIN000050692
JPRN-UMIN000050692
Completed
未知

A retrospective study to evaluate the impact of proteinuria induced by Atezolizumab plus Bevacizumab on renal function and other renal-related adverse events in patients with unresectable hepatocellular carcinoma. - Atezolizumab plus Bevacizumab-Related Impact on Renal Function and Adverse Events Trial

Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology0 sites120 target enrollmentMarch 31, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
hepatocellular carcinoma
Sponsor
Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology
Enrollment
120
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 31, 2023
End Date
July 31, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Patients with missing UPCR and eGFR data at baseline (2\)Patients with all missing UPCR and eGFR data after starting Atezo\+Bev treatment (3\)Patients with Child\-Pugh Classification Class C at the start of Atezo\+Bev treatment (4\)Patients deemed ineligible for this study by their physician

Outcomes

Primary Outcomes

Not specified

Similar Trials